Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials

Annals of Oncology

Volumn 26, Issue 12, 2015, Pages 2450-2456

  Sunakawa, Y ^a,b   Stintzing, S ^c   Cao, S ^a   Heinemann, V ^c   Cremolini, C ^d   Falcone, A ^d   Yang, D ^a   Zhang, W ^a   Ning, Y ^a   Stremitzer, S ^a   Matsusaka, S ^a   Yamauchi, S ^a   Parekh, A ^a   Okazaki, S ^a   Berger, M D ^a   Graver, S ^e   Mendez, A ^a   Scherer, S J ^e   Loupakis, F ^d   Lenz, H J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

colorectal cancer; KRAS; polymorphism; TBK1; tumor associated macrophage

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CHEMOKINE RECEPTOR CCR2; GENOMIC DNA; INTERFERON REGULATORY FACTOR 3; LACTATE DEHYDROGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; CCL18 GENE; CCL2 GENE; CCR2 GENE; COHORT ANALYSIS; CONTROLLED STUDY; DNA EXTRACTION; EXON; GENE; GENE CONTROL; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HRG GENE; HUMAN; IRF3 GENE; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; NFKB1 GENE; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PIGF GENE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TBK1 GENE; TREND STUDY; TUMOR ASSOCIATED LEUKOCYTE; WILD TYPE; ADULT; AGED; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DRUG EFFECTS; FEMALE; GENETIC VARIATION; GENETICS; MACROPHAGE; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; BEVACIZUMAB; BIOMARKERS, TUMOR; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; GENETIC VARIATION; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84949933276     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv474     Document Type: Article

References (22)

1. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604.
2. Mantovani A, Sozzani S, Locati M et al. Macrophage polarization: tumorassociated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555.
3. Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the matchmaker. Nat Immunol 2011; 12: 715-723.
4. Barbera-Guillem E, Nyhus JK, Wolford CC et al. Vascular endothelial growth factor secretion by tumor-infiltrating macrophages essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res 2002; 62: 7042-7049.
5. Forssell J, Oberg A, Henriksson ML et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res 2007; 13: 1472-1479.
6. Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) and inflammation in colorectal cancer. Cancer Microenviron 2011; 4: 141-154.
7. Sunakawa Y, Stremitzer S, Cao S et al. Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. Ann Oncol 2015; 26: 332-339.
8. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618.
9. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075.
10. Lee PH, Shatkay H. F-SNP: computationally predicted functional SNPs for disease association studies. Nucleic Acids Res 2008; 36: D820-D824.
11. Sato S, Sugiyama M, Yamamoto M et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANK-binding kinase 1, and activates two distinct transcription factors, NFkappa B and IFN-regulatory factor-3, in the Toll-like receptor signaling. J Immunol 2003; 171: 4304-4310.
12. Korherr C, Gille H, Schafer R et al. Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc Natl Acad Sci USA 2006; 103: 4240-4245.
13. Barbie DA, Tamayo P, Boehm JS et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-112.
14. Tan J, Li Z, Lee PL et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTORtargeted therapy. Cancer Discov 2013; 3: 1156-1171.
15. Kodelja V, Muller C, Politz O et al. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998; 160: 1411-1418.
16. Andersen J, VanScoy S, Cheng TF et al. IRF-3-dependent and augmented target genes during viral infection. Genes Immun 2008; 9: 168-175.
17. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003; 3: 11-22.
18. Chappell WH, Steelman LS, Long JM et al. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/ mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011; 2: 135-164.
19. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004; 6: 447-458.
20. Tang CH, Tsai CC. CCL2 increases MMP-9 expression and cell motility in human chondrosarcoma cells via the Ras/Raf/MEK/ERK/NF-kappaB signaling pathway. Biochem Pharmacol 2012; 83: 335-344.
21. Petanidis S, Anestakis D, Argyraki M et al. Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-gamma. PLoS One 2013; 8: e73616.
22. van Huis-Tanja L, Kweekel D, Gelderblom H et al. Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples. Pharmacogenomics 2013; 14: 2005-2012.